Lv2
180 积分 2026-04-16 加入
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
1个月前
已完结
Mirvetuximab soravtansine dosing weight considerations
1个月前
已完结
Learnings from Approved Antibody‐Drug Conjugates: Clinical Pharmacology Perspectives
1个月前
已完结
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
5个月前
已完结
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
5个月前
已完结
皖公网安备34019202002308
